2-(cyclopentylamino)propanoic acid;(2S)-2-(methylamino)pentanedioic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(cyclopentylamino)propanoic acid;(2S)-2-(methylamino)pentanedioic acid
• 化学式: C14H26N2O6
• 分子量: 318.37
• InChiKey: JWHGGVVJBHDJRP-VWMHFEHESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.52
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  136
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• COMPLEX-FORMATION-MODULATING AGENTS AND USES THEREFOR
  申请人：Queensland University Of Technology

  公开号：EP2922862A1

  公开（公告）日：2015-09-30
• PROTEINACEOUS MOLECULES AND METHODS OF USE
  申请人：The University of Queensland

  公开号：EP3387007A1

  公开（公告）日：2018-10-17
• PROTEINACEOUS COMPOUNDS AND USES THEREFOR
  申请人：University of Canberra

  公开号：EP3411061A1

  公开（公告）日：2018-12-12
• SPIDER VENOM PEPTIDES AND METHODS OF USE FOR MODULATING SODIUM CHANNELS.
  申请人：The University of Queensland

  公开号：EP3472192A1

  公开（公告）日：2019-04-24
• [EN] COMPLEX-FORMATION-MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE FORMATION-MODULATION DE COMPLEXES ET LEURS UTILISATIONS
  申请人：UNIV QUEENSLAND

  公开号：WO2014078896A1

  公开（公告）日：2014-05-30

  Disclosed are methods and agents for modulating proliferation, migration and/or survival of cells. More particularly, the present invention discloses molecules that have any one or more activities selected from: inhibiting binding of vitronectin to at least one vitronectin-binding partner selected from an IGF and IGFBP, inhibiting formation of a complex comprising vitronectin and at least one vitronectin-binding partner selected from an IGF and IGFBP, or inhibiting proliferation or survival of a hyperproliferative cell (e.g., a neoplastic cell or non-neoplastic cell), or inhibiting migration or invasion of a hyperproliferative cell (e.g., a neoplastic cell or a non-neoplastic cell). Additionally, the present invention discloses the use of these molecules in methods and compositions for treating or preventing hyperproliferative cell disorders including neoplastic (e.g., cancers such as epithelial cancers) and non-neoplastic disorders.